Biocon Rating
CITI ON BIOCON : 09.06.2021
• Maintain BUY, Target at Rs 470/share
• Open a Positive Catalyst Watch
* Glargine Interchangeability and Aspart Approval are Big Events
• Approval biosimilar Aspart (bNovolog) is next for Biocon
* USFDA action date in July 2021
CLSA ON BIOCON : 03.06.2021
* MAINTAIN SELL TARGET: 260
* Another filing in Pegfilgrastim comes in; market share for Biocon may remain elusive & risk of a further earnings downgrade is high, CLSA says
* Rising Competitive Landscape
* Another Filing In Pegfilgrastim Today; Market Share May Remain Elusive
* Time Is Running Out To Ramp Up Market Share In Existing Products
* Mkt Shr Gains In Biologics To Be Only Gradual On Rising Competition
* Risk Of Further Earnings Downgrades Is High
